Sangamo Therapeutics股票討論區

$Sangamo Therapeutics(SGMO.US)$ Sangamo Therapeutics To Present Neurology-Focused Pre-Clinical Data From Epigenetic Regulation, Capsid Delivery And Genome Engineering Platforms At 27th ASGCT Annual Meeting

$Sangamo Therapeutics(SGMO.US)$ Hehehe! just thinking outloud

$Sangamo Therapeutics(SGMO.US)$ Sangamo Therapeutics Announces Data From STAC-BBB Demonstrating 'Robust Penetration of the Blood-brain Barrier (BBB) and Strong Transgene Expression Throughout the Central Nervous System (CNS) of NHPs'

$Sangamo Therapeutics(SGMO.US)$ is likely to get FDA approval soon.

$Sangamo Therapeutics(SGMO.US)$ 22 Feb 2024 positive results of IL23R - CAR will be announced at the ECCO 2024 meeting

$Sangamo Therapeutics(SGMO.US)$ WooHooo! Broke the buck barier! Hehehe

$Sangamo Therapeutics(SGMO.US)$ Nice to see the trend over the last 10+ days is getting a bit of acceleration

$Sangamo Therapeutics(SGMO.US)$ Sangamo Therapeutics Announces FDA Alignment On Abbreviated Pathway To Potential Approval And EMA Prime Eligibility For ST-920 In Fabry Disease
Benzinga· 2 mins ago
- U.S. Food and Drug Administration (FDA) advises that a single study with up to 25 patients, in combination with confirmatory evidence, may be acceptable pathway to Biologics License Application (BLA) submission for isaralgagene civaparvovec, which would significantly reduce anticipated complexi...